Paricalcitol in Treating Patients With Myelodysplastic Syndrome

NCT00064376 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: paricalcitol

Sponsor

Cedars-Sinai Medical Center

Collaborators

[object Object]